Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Press release — not a study alzhub usefulness score 16 out of 100. Clinical trials

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The Phase 2a TOGETHER trial tested bepranemab, an antibody targeting the tau protein (rather than amyloid), in 466 people with prodromal-to-mild Alzheimer's disease over 80 weeks. The drug did not improve the main cognitive/functional measure (CDR-SB) compared with placebo across the whole study group, but it did slow the buildup of tau seen on PET brain scans by 33-58%, with a larger tau-PET effect (63-67%) in a subgroup with lower baseline tau or without the ApoE4 gene. Side effects were similar between drug and placebo groups.

What this study adds

Evidence grade: Early

The record lists 466 participants. In the Phase 2a TOGETHER trial, the anti-tau antibody bepranemab did not improve the main cognitive/functional measure compared with placebo across the whole group, but it slowed tau buildup on PET scans by 33-58% overall. Reported effect size: Tau-PET accumulation slowed 33-58% overall, 63-67% in a lower-tau/non-ApoE4 subgroup; primary CDR-SB endpoint not met.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study. (2024). UCB press release (data presented at CTAD 2024).

Vancouver

UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study. UCB press release (data presented at CTAD 2024). 2024.

BibTeX

@article{study2024-c943abc5,
  title   = {{UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study}},
  journal = {UCB press release (data presented at CTAD 2024)},
  year    = {2024}
}

Built from the record alzhub holds for this paper, not looked up. This record has no authors, DOI, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In the Phase 2a TOGETHER trial, the anti-tau antibody bepranemab did not improve the main cognitive/functional measure compared with placebo across the whole group, but it slowed tau buildup on PET scans by 33-58% overall. This is a Phase 2a trial, and the clinical endpoint was not met in the overall population.

Study details

Limitations

Primary clinical endpoint not met in the overall population; positive signal only in a subgroup; conference-presented data (CTAD 2024), not yet an independent peer-reviewed publication.

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 8 of 12; Strength of evidence 2 of 5; Peer-review validation 1 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 24 of the 66 points it could be judged on, which is 36 of 100. Raw total 36 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 36 of 100capped at 16 — hatched points do not count

Press release — not a study. It scored 36 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 24 of the 66 points we could judge it on, which is 36 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (UCB press release (data presented at CTAD 2024))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 8 / 12 A mid-stage phase 2 trial
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 1 / 10 Press release — not a study. Named source is a company press release.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 2 / 4 466 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 24 / 66 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 24 of the 66 points we could judge it on is 36 out of 100.
Total 36 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Clinical trials from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →